Neumora Therapeutics, Inc. (NASDAQ:NMRA) Short Interest Update

Neumora Therapeutics, Inc. (NASDAQ:NMRA - Get Free Report) saw a significant decline in short interest during the month of January. As of January 15th, there was short interest totalling 11,030,000 shares, a decline of 15.1% from the December 31st total of 12,990,000 shares. Currently, 20.0% of the shares of the stock are sold short. Based on an average trading volume of 2,830,000 shares, the short-interest ratio is currently 3.9 days.

Neumora Therapeutics Stock Up 1.6 %

Shares of NMRA stock traded up $0.03 during trading on Wednesday, reaching $1.94. 1,534,328 shares of the company's stock were exchanged, compared to its average volume of 6,409,651. The firm's fifty day moving average price is $6.45 and its 200-day moving average price is $10.25. Neumora Therapeutics has a twelve month low of $1.81 and a twelve month high of $21.00. The stock has a market capitalization of $313.43 million, a PE ratio of -1.04 and a beta of 2.54.

Neumora Therapeutics (NASDAQ:NMRA - Get Free Report) last announced its earnings results on Tuesday, November 12th. The company reported ($0.45) EPS for the quarter, missing the consensus estimate of ($0.39) by ($0.06). During the same period last year, the company earned ($1.14) EPS. As a group, analysts anticipate that Neumora Therapeutics will post -1.61 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts have recently commented on NMRA shares. Bank of America lowered their target price on Neumora Therapeutics from $22.00 to $7.00 and set a "buy" rating for the company in a research note on Monday, January 6th. William Blair reissued an "outperform" rating on shares of Neumora Therapeutics in a report on Wednesday, January 15th. HC Wainwright reaffirmed a "buy" rating and issued a $30.00 target price on shares of Neumora Therapeutics in a research note on Friday, January 3rd. Needham & Company LLC restated a "buy" rating and issued a $23.00 price objective on shares of Neumora Therapeutics in a report on Thursday, January 2nd. Finally, JPMorgan Chase & Co. lowered shares of Neumora Therapeutics from an "overweight" rating to a "neutral" rating and lowered their target price for the stock from $18.00 to $15.00 in a report on Tuesday, November 5th. Two research analysts have rated the stock with a hold rating and five have issued a buy rating to the company's stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $16.50.

Institutional Investors Weigh In On Neumora Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in NMRA. Windmill Hill Asset Management Ltd increased its stake in Neumora Therapeutics by 299.6% during the 4th quarter. Windmill Hill Asset Management Ltd now owns 104,373 shares of the company's stock worth $1,106,000 after acquiring an additional 78,252 shares during the period. Mirae Asset Global Investments Co. Ltd. bought a new position in shares of Neumora Therapeutics in the fourth quarter worth $61,000. SkyOak Wealth LLC raised its stake in Neumora Therapeutics by 33.3% in the fourth quarter. SkyOak Wealth LLC now owns 20,000 shares of the company's stock valued at $212,000 after purchasing an additional 5,000 shares in the last quarter. China Universal Asset Management Co. Ltd. bought a new stake in Neumora Therapeutics during the fourth quarter worth about $363,000. Finally, JPMorgan Chase & Co. grew its stake in Neumora Therapeutics by 2.6% during the third quarter. JPMorgan Chase & Co. now owns 64,421 shares of the company's stock worth $851,000 after buying an additional 1,629 shares in the last quarter. 47.65% of the stock is currently owned by institutional investors and hedge funds.

About Neumora Therapeutics

Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.